JPS6355493B2 - - Google Patents
Info
- Publication number
- JPS6355493B2 JPS6355493B2 JP56106684A JP10668481A JPS6355493B2 JP S6355493 B2 JPS6355493 B2 JP S6355493B2 JP 56106684 A JP56106684 A JP 56106684A JP 10668481 A JP10668481 A JP 10668481A JP S6355493 B2 JPS6355493 B2 JP S6355493B2
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- laxative
- lactic acid
- enzyme
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000894006 Bacteria Species 0.000 claims description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000008141 laxative Substances 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 230000002475 laxative effect Effects 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000013872 defecation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010056325 Faecaloma Diseases 0.000 description 3
- 208000008415 Fecal Impaction Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Description
【発明の詳細な説明】
本発明は、主として乳酸菌類と少なくとも30ｇ
以上の乳糖を用いて作成した下剤に関する。一般
に下剤は、腸壁に接するか、腸壁より吸収され
て、神経を刺激することによつて腸のダ動を促進
し、排便を促すものを基本としているが、このた
め腹痛を起こしたり、耐性、習慣性ができて順次
増量の必要が生じたり、長期の服用によつては、
腸の神経が麻痺して、重度の便泌症となるといつ
た副作用があつた。又、近来、肉食が普及し、植
物性繊維の不足のため慢性便泌の患者が増え、腸
に内臓する宿便が種々の疾病，癌でさえもの原因
と目されるに至り、このため、長期服用しても副
作用の発生しない下剤又は排便促進剤が求められ
ていた。DETAILED DESCRIPTION OF THE INVENTION The present invention mainly comprises lactic acid bacteria and at least 30 g of lactic acid bacteria.
The present invention relates to a laxative prepared using the above lactose. In general, laxatives are basically drugs that come into contact with the intestinal wall or are absorbed through the intestinal wall and stimulate the nerves, thereby promoting intestinal movement and promoting defecation. If you develop tolerance or habit and need to increase the dose gradually, or if you take it for a long time,
Side effects included paralysis of the nerves in the intestine and severe fecal secretion. In addition, in recent years, as meat-eating has become widespread, the number of patients with chronic fecal secretion has increased due to lack of vegetable fiber, and fecal impaction in the intestines has come to be seen as the cause of various diseases and even cancer. There has been a need for a laxative or a defecation stimulant that does not cause side effects when taken.
本発明はこれらの必要を完全にみたさんとする
もので、これを順次説明すると、
一般に、乳酸菌は乳糖を、納豆菌は蛋白質を、
酵母は多糖類を分解することによつて増殖し、こ
の際多量のCO2ガスを副生せしめるが、本発明は
人体に無害なこのCO2ガスの持つ物理的圧力と
CO2ガス発生期の刺激作用を活用して下剤にしよ
うとするものである。現在、医薬品や食品として
利用される酵素末と称されるものは、各種の微生
物を培養して酵素を生産せしめた培養基からアル
コール，アセトン等の溶剤を用いて酵素のみを純
粋な形で抽出するものであるが、本発明では、少
なくともヴイフイルズ菌等の乳酸菌類と少なくと
も全量中30ｇ以上の乳糖よりなることを構成すべ
く、まず乳酸菌を調整するもので、例えばヴイフ
イルズ菌等の乳酸菌類、納豆菌類、酵母類等の醗
酵後の培養基（この場合少なくとも乳酸菌類が含
まれることが条件となる）をそのまま乾燥して、
生菌，芽胞，酵素のすべてを含む半乾燥物又は乾
燥粉末を作り、これを基本物質（以下これを醗酵
素と称す）として用いたり、又は納豆菌類や酵母
類を含まない乳酸菌類の生菌，芽胞，培養基の一
種又は二種以上（以下これをも醗酵素と称す）を
選択するものである。ここに醗酵素は、組成的に
は、生菌，芽菌，酵素，培養基に分けることがで
きるが、生菌は商品として流通中に仮死状態にな
り、芽胞、酵素は乾燥状態に耐えることが出来る
もので、胃袋から小腸に入つて醗酵素が溶解され
るにつれ、先づ酵素が直ちに作用を開始し、続い
て生菌がよみがえり、やがて芽胞が吸水して芽生
え、増殖し始めることになる。培養基は商品流通
中には、外気との保護作用を行い服用後は細菌類
のなじみのある栄養素としても働くものと考えら
れる。 The present invention completely satisfies these needs, and explains them one by one: In general, lactic acid bacteria produce lactose, Bacillus natto produces protein,
Yeast proliferates by decomposing polysaccharides, and at this time produces a large amount of CO 2 gas as a by-product, but the present invention exploits the physical pressure and physical pressure of this CO 2 gas, which is harmless to the human body.
This is an attempt to make it into a laxative by utilizing the stimulatory effect during the CO 2 gas generation period. Currently, what is called enzyme powder used in medicines and foods is made by extracting enzymes in pure form using solvents such as alcohol and acetone from a culture medium in which various microorganisms have been cultured to produce enzymes. However, in the present invention, lactic acid bacteria are first prepared so that the product consists of at least lactic acid bacteria such as Vophilus bacteria and at least 30 g of lactose in the total amount. , the culture medium after fermentation of yeast etc. (in this case, the condition is that it contains at least lactic acid bacteria) is dried as it is,
You can make a semi-dry product or dry powder containing all of live bacteria, spores, and enzymes and use this as a basic substance (hereinafter referred to as enzyme), or you can use live bacteria of lactic acid bacteria that do not contain natto fungus or yeast. , spores, and culture medium (hereinafter also referred to as enzymes). In terms of composition, enzymes can be divided into live bacteria, germs, enzymes, and culture media, but live bacteria enter a state of suspended animation during distribution as a product, while spores and enzymes cannot withstand dry conditions. As the enzyme enters the small intestine from the stomach and is dissolved, the enzyme immediately begins its action, followed by viable bacteria, and eventually spores absorb water, sprout, and begin to multiply. It is thought that the culture medium acts as a protective agent against the outside air during product distribution, and also acts as a familiar nutrient for bacteria after consumption.
本発明は、上記の様な順序で作用するのである
から、速効のある酵素は多い程よいが、これは定
量的に働くので、下痢作用をもたらす程度に服用
することは先づ困難であり、生菌，芽胞が大半の
働きをするものと考えられる。ちなみに微生物、
例えば乳酸菌１ケは、１夜で約１億ケに増えるも
のではあるが、胃液中を通過して腸内に到着して
増殖しはじめるまでに相当な消耗を考えねばなら
ず、効果の信頼性のために醗酵素１ｇ中に生菌，
芽胞を105〜108ケを含有したものを使用すべきで
ある。 Since the present invention acts in the order described above, the more rapidly acting enzymes are used, the better; however, since they act quantitatively, it is difficult to take enough to cause diarrheal effects, and It is thought that bacteria and spores do most of the work. By the way, microorganisms
For example, one lactic acid bacterium increases to about 100 million bacteria in one night, but a considerable amount of wastage must be taken into consideration before it passes through the gastric fluid, reaches the intestine, and begins to multiply, making the reliability of its effectiveness unreliable. For this reason, 1 g of enzyme contains live bacteria,
One containing 10 5 to 10 8 spores should be used.
本発明は、このような醗酵素を乳糖と水分に共
存させることで醗酵素中の乳酸菌の増殖を可能と
し、このとき発生するCO2ガスの作用が下剤とし
ての効果を発揮させるものである。 The present invention enables the growth of lactic acid bacteria in the enzyme by coexisting the enzyme with lactose and water, and the action of the CO 2 gas generated at this time exerts the effect as a laxative.
なお、醗酵素に対して使用する乳糖の量は少な
ければ下剤としての効果の発揮が困難であるか
ら、その使用量は、なるべく大量であることが望
まれ、少なくとも全量中30ｇ以上の量を用いる必
要がある。しかし、服用者の体質等によつて各々
異なるものであることから、標準的には成人を対
象とした場合、一回服用量として30〜80ｇ、或い
はそれ以上を用いることが望ましい。 In addition, if the amount of lactose used for the enzyme is small, it will be difficult to exert its effect as a laxative, so it is desirable to use as large a amount as possible, and use at least 30g or more of the total amount. There is a need. However, since each dose differs depending on the constitution of the person taking the drug, it is generally desirable to use 30 to 80 g or more as a single dose for adults.
本発明は一例として次の処方で実施される。 The present invention is implemented with the following formulation as an example.
処方(1) 醗酵素 １ｇ
粉ミルク（又は豆乳末） 80ｇ
乳 糖 30ｇ
温湯又は冷水 200ｇ
これらを混合したものを空腹時に１回分として
服用すると、普通１時間前後から腹鳴があり、腹
張りの自覚が進み、やがて便意をもよおして、通
常２〜３時間前後してかなりのガスと共に大量の
排便を見ることになり、これが時間をおいて２〜
３回繰り返され、腸内の便が殆んど一掃される
が、完全に終了した後は極めて爽快な感覚が残
る。これは、通常１日１回朝食代りに服用する
が、人によつて個人差があり、２〜３日かかつて
このような結果を見る人もあり、排便後は通常の
下剤のように残留感が全くなく又、この服用を止
めると直ちに平常のペースに復帰して通常便を見
ることが出来る。この方法は、ガスが出るという
こと以外は腹痛もなく、習慣性もなく、常用して
も大腸性の下痢のために栄養障害もない。又、味
も美味で、朝食代りとして常用することで、宿便
のために生じるといわれるふき出もの、じんまし
ん、ぜんそく等のアレルギーはじめ高血圧、不
眠、肩こり、太りすぎ迄にも著効を見ることが出
来る。Prescription (1) Enzyme 1g Powdered milk (or soybean milk powder) 80g Lactose 30g Hot or cold water 200g If you take a mixture of these as a single dose on an empty stomach, you will usually experience borborygmo for about an hour and become aware of abdominal bloating. As the progress progresses, you will eventually feel the urge to defecate, and usually after about 2 to 3 hours you will have a large amount of defecation with considerable gas.
The process is repeated three times, and most of the fecal matter in the intestines is wiped out, but after it is completely finished, an extremely refreshing feeling remains. This is usually taken once a day in place of breakfast, but it varies from person to person, and some people have seen similar results for 2 to 3 days, and after defecation, it remains like a normal laxative. I don't feel any sensation at all, and as soon as I stop taking this medication, I can return to my normal pace and have normal stools. This method does not cause abdominal pain other than gas, is not addictive, and does not cause malnutrition due to large intestine diarrhea even if used regularly. In addition, it has a delicious taste, and by regularly using it as a breakfast substitute, it can be effective against pimples, hives, allergies such as asthma, which are said to occur due to fecal impaction, as well as high blood pressure, insomnia, stiff shoulders, and even overweight. I can do it.
なお、本発明は無酸素の状態でも生育する人体
有益菌を使用するので、上記の有害菌の生育をお
さえ、腸内の状態を細菌的に清浄するのみでな
く、この際、有益菌が生産する各種の酵素は腸の
内壁にある宿便を分解排出する効果もあり、又処
方(1)の例にみるミルク配合を除けば、乳糖は上記
のように分解されCO2ガス発生と同時に分解吸収
されるが、乳成分中の蛋白質も納豆菌によつて分
解、吸収され、栄養的にも長期の使用に不安はな
い。 Furthermore, since the present invention uses bacteria that are beneficial to the human body and can grow even in anoxic conditions, it not only suppresses the growth of the above-mentioned harmful bacteria and purifies the intestinal condition from a bacterial perspective, but also reduces the production of beneficial bacteria. The various enzymes that do this have the effect of decomposing and excreting fecal impaction on the inner wall of the intestine.Also, except for the milk combination shown in the example of prescription (1), lactose is decomposed as described above, and CO 2 gas is generated and simultaneously decomposed and absorbed. However, the protein in the milk components is also broken down and absorbed by Bacillus natto, so there is no nutritional concern for long-term use.
以上処方(1)は各成分の混合物を作成と同時に服
用したが、服用前２〜３時間又は数時間以上コツ
プ等に入れて放置しておくことにより、乳酸菌、
乳糖の溶液中では醗酵が始まり、これを服用する
ことで下剤としての機能は、服用後速やかに発揮
され、本発明の目的を即座に達成できる。 The above prescription (1) was taken at the same time as the mixture of each ingredient was prepared, but by leaving it in a pot for 2 to 3 hours or more than a few hours before taking it, lactic acid bacteria,
Fermentation begins in the lactose solution, and by taking this, the laxative function is exerted immediately after taking it, and the purpose of the present invention can be achieved immediately.
処方(2) 醗酵素 １ｇ
乳 糖 80ｇ
黒 糖 10ｇ
天然粉末ジユース ５ｇ
各種ビタミン類 適 量
温湯又は冷水 250ｇ
処方(2)は、ミルクにアレルギーのある人や栄養
過多の人のためのもので、これの混合物を一回量
として服用すると処方(1)と同様、１時間前後で腹
張りの自覚が進み、２〜３時間で大量の排便をみ
る。上記のものを更に強力に作用せしめんとする
場合は、これに粉末コンニヤク（マンナン澱粉
末）１ｇを加えて服用すると、糖分の吸収をさま
たげ、便通を促進し、太り過ぎの治療、美肌作り
のために極めて有効である。Prescription (2) Enzyme 1g Lactose 80g Brown sugar 10g Natural powdered juice 5g Various vitamins Appropriate amount Hot or cold water 250g Prescription (2) is for people who are allergic to milk or are overnourished. When the mixture is taken as a single dose, similar to prescription (1), the patient becomes aware of abdominal distension within about an hour and begins to defecate in large quantities within 2 to 3 hours. If you want the above to be more effective, add 1g of powdered konnyaku (mannan starch powder) to it and take it.It will block sugar absorption, promote bowel movements, treat overweight, and create beautiful skin. It is extremely effective.
本発明は以上のように極めて安全、安価な方法
であり、健康保持又は病気治療のために長期使用
出来る効果的な下剤であつて、長期にわたり、食
物の腐敗物が残留粘着したと考えられる宿便は、
腸壁表面に固着しており、大黄等の強い下剤で長
期にわたつて洗腸しても完全に取ることが困難で
あつたが、本発明による洗腸では、水様のミルク
便がガスによつて拡張された腸壁を急速に通過し
て洗い流すため、４日〜７日程度の治療で腸壁が
極めて清浄になつているのが内視鏡で観察するこ
とが出来るうえに、この宿便の排出は、排便が黒
く粘性があり異臭のあることによつても確認する
ことが出来る。 As described above, the present invention is an extremely safe and inexpensive method, and is an effective laxative that can be used for a long period of time to maintain health or treat diseases. teeth,
It adheres to the surface of the intestinal wall, and it has been difficult to completely remove it even after long-term colon cleansing with strong laxatives such as rhubarb. However, with the colon cleansing method of the present invention, watery milky stools become gas. As the fecal matter rapidly passes through the dilated intestinal wall and is flushed away, it is possible to observe with an endoscope that the intestinal wall becomes extremely clean after about 4 to 7 days of treatment, and this impaction is also removed. Excretion can also be confirmed by the fact that the stool is black, viscous, and has a foul odor.
なお、本発明は粉末を主として説明したが、こ
れを乳糖その他を液剤にして醗酵素を別封し、こ
れを同時に服用するとか、処方通りの成分を角砂
糖又は錠剤、あめ状に加工し服用に便宜を与える
のは自由である。 Although the present invention has been mainly explained as a powder, it can be made into a liquid with lactose or other ingredients, packaged with enzyme separately, and taken at the same time, or the ingredients as prescribed can be processed into sugar cubes, tablets, or candy and taken. You are free to give accommodations.
Claims (1)
と、ヴイフイズス菌等の乳酸菌類の生菌、芽胞、
培養基から選んだ一又は二以上のものと、からな
る下剤。 ２ 温湯又は冷水中に溶解、分散して溶液状態と
してなる特許請求の範囲第１項記載の下剤。[Claims] 1. At least 30g of lactose per dose, live bacteria and spores of lactic acid bacteria such as Vifidobacterium,
A laxative consisting of one or more selected culture media. 2. The laxative according to claim 1, which is dissolved or dispersed in hot water or cold water to form a solution state.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56106684A JPS588018A (en) | 1981-07-07 | 1981-07-07 | Cathartic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56106684A JPS588018A (en) | 1981-07-07 | 1981-07-07 | Cathartic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60011553A Division JPS60214740A (en) | 1985-01-23 | 1985-01-23 | Purgative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS588018A JPS588018A (en) | 1983-01-18 |
| JPS6355493B2 true JPS6355493B2 (en) | 1988-11-02 |
Family
ID=14439885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56106684A Granted JPS588018A (en) | 1981-07-07 | 1981-07-07 | Cathartic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS588018A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6163618A (en) * | 1984-09-03 | 1986-04-01 | Akira Yamauchi | Cathartic |
| JPS60214740A (en) * | 1985-01-23 | 1985-10-28 | Akira Yamauchi | Purgative |
| US5656268A (en) * | 1995-04-21 | 1997-08-12 | Sorodsky; Michael | Biological product |
| DE50300325D1 (en) * | 2003-11-03 | 2005-03-31 | Peter-Hansen Volkmann | Vaginalpflegezusammensetzung |
-
1981
- 1981-07-07 JP JP56106684A patent/JPS588018A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS588018A (en) | 1983-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101870846B1 (en) | Multi-functional composition and preparation method and application thereof | |
| CN107568736A (en) | Dealcoholic sobering-up medical science formula food | |
| CN112569323A (en) | Composition for dispelling effects of alcohol and protecting liver and application thereof | |
| CN113519736A (en) | Intestinal health conditioning food and preparation method and application thereof | |
| CN100534438C (en) | Difructose anhydride-containing composition and use thereof | |
| JPS6355493B2 (en) | ||
| CN102715606A (en) | Beverage | |
| CN109700031A (en) | For cleaning intestinal tract, the alimentation composition of enteron aisle toxin expelling | |
| CN114343180A (en) | A series of compositions with effects of clearing hollow viscera and removing toxic substance, and its application | |
| CN109730222A (en) | Ferment complex liquid and its health drink | |
| CN114191515A (en) | Oral gel for dispelling dampness, invigorating stomach and improving immunity and preparation method thereof | |
| KR100437933B1 (en) | The health-assisting food having improvement effects of constipation and intestines activity and its compositions | |
| CN104116999A (en) | Preparation for improving intestinal microbial environment and preparation method thereof | |
| Haggard | The science of health and disease: a textbook of physiology and hygiene | |
| CN101468029B (en) | Difructose anhydride-containing composition and use thereof | |
| TW202114542A (en) | Prebiotic composition for promoting growth ofclostridium butyricumand uses thereof | |
| JPS60214740A (en) | Purgative | |
| JPS6163618A (en) | Cathartic | |
| Stannard | Materia medica and philosophic theory in Aretaeus | |
| CN101313982B (en) | Traditional Chinese medicine onion slurry, preparing method and uses thereof | |
| JP2010100576A (en) | Constipation-improving agent | |
| KR100602449B1 (en) | Manufacturing method of the for honey tea honey granule honey with the main material | |
| Meyerowitz | Juice Fasting and Detoxification: Use the Healing Power of Fresh Juice to Feel Young and Look Great | |
| RU2070050C1 (en) | Agent for stimulation of motor-evacuator intestine function in children | |
| CN104940332A (en) | Fructo oligosaccharide composition for relaxing bowels and reducing flatulence and preparation method thereof |